Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 502057, 8 pages
http://dx.doi.org/10.1155/2011/502057
Research Article

Orange Juice and Its Component, Hesperidin, Decrease the Expression of Multidrug Resistance-Associated Protein 2 in Rat Small Intestine and Liver

1Department of Pharmacology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-Ku, Kawasaki, Kanagawa 216-8511, Japan
2Institution for Animal Experimentation, St. Marianna University Graduate School of Medicine, Kawasaki, Kanagawa 216-8511, Japan
3Department of Pharmacogenomics, St. Marianna University Graduate School of Medicine, Kawasaki, Kanagawa 216-8511, Japan
4Unit of Medical Statistics, Faculty of Medical Education and Culture, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan

Received 13 September 2010; Revised 25 February 2011; Accepted 24 March 2011

Academic Editor: Phillip E. Klebba

Copyright © 2011 Minoru Watanabe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Tian, N. Koyabu, H. Takanaga, H. Matsuo, H. Ohtani, and Y. Sawada, “Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates,” Pharmaceutical Research, vol. 19, no. 6, pp. 802–809, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. G. K. Dresser and D. G. Bailey, “The effects of fruit juices on drug disposition: a new model for drug interactions,” European Journal of Clinical Investigation, vol. 33, no. 2, pp. 10–16, 2003. View at Google Scholar · View at Scopus
  3. M. Haria and D. McTavish, “Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease,” Drugs, vol. 53, no. 2, pp. 299–336, 1997. View at Google Scholar · View at Scopus
  4. Y. U. Koitabashi, T. Kumai, N. Matsumoto et al., “Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects,” Life Sciences, vol. 78, no. 24, pp. 2852–2859, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. K. T. Kivistö, O. Grisk, U. Hofmann et al., “Disposition of oral and intravenous pravastatin in MRP2-Deficient TR rats,” Drug Metabolism and Disposition, vol. 33, no. 11, pp. 1593–1596, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. Hirano, K. Maeda, S. Matsushima, Y. Nozaki, H. Kusuhara, and Y. Sugiyama, “Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin,” Molecular Pharmacology, vol. 68, no. 3, pp. 800–807, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. J. Lilja, K. T. Kivistö, and P. J. Neuvonen, “Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin,” Clinical Pharmacology and Therapeutics, vol. 66, no. 2, pp. 118–127, 1999. View at Google Scholar · View at Scopus
  8. B. Ameer, R. A. Weintraub, J. V. Johnson, R. A. Yost, and R. L. Rouseff, “Flavanone absorption after naringin, hesperidin, and citrus administration,” Clinical Pharmacology and Therapeutics, vol. 60, no. 1, pp. 34–40, 1996. View at Google Scholar · View at Scopus
  9. I. Erlund, E. Meririnne, G. Alfthan, and A. Aro, “Human nutrition and metabolism: plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice,” Journal of Nutrition, vol. 131, no. 2, pp. 235–241, 2001. View at Google Scholar · View at Scopus
  10. K. Otter and C. Mignat, “Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection,” Journal of Chromatography B: Biomedical Applications, vol. 708, no. 1-2, pp. 235–241, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Iacona, M. B. Regazzi, I. Buggia et al., “High-performance liquid chromatography determination of pravastatin in plasma,” Therapeutic Drug Monitoring, vol. 16, no. 2, pp. 191–195, 1994. View at Google Scholar · View at Scopus
  12. S. Tatsunami, A. Ito, K. Kawata, R. Kuwabara, and K. Yamada, “Determination of pharmacokinetic parameters of stavudine in Japanese patients infected with HIV-1, using a Gaussian-like input rate function,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 26, no. 1-2, pp. 137–140, 2001. View at Google Scholar · View at Scopus
  13. L. Sadphati and L. Z. Benet, “Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers,” Biochemical Pharmacology, vol. 55, no. 4, pp. 387–395, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Kitaoka, T. Kumai, Y. Kitaoka et al., “Nuclear factor-kappa B p65 in NMDA-induced retinal neurotoxicity,” Molecular Brain Research, vol. 131, no. 1-2, pp. 8–16, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. M. Careri, L. Elviri, A. Mangia, and M. Musci, “Spectrophotometric and coulometric detection in the high-performance liquid chromatography of flavonoids and optimization of sample treatment for the determination of quercetin in orange juice,” Journal of Chromatography A, vol. 881, no. 1-2, pp. 449–460, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Tokui, D. Nakai, R. Nakagomi, H. Yawo, T. Abe, and Y. Sugiyama, “Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2,” Pharmaceutical Research, vol. 16, no. 6, pp. 904–908, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Hagenbuch and P. J. Meier, “The superfamily of organic anion transporting polypeptides,” Biochimica et Biophysica Acta, vol. 1609, no. 1, pp. 1–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Yamazaki, S. Akiyama, K. Ni'Inuma, R. Nishigaki, and Y. Sugiyama, “Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT),” Drug Metabolism and Disposition, vol. 25, no. 10, pp. 1123–1129, 1997. View at Google Scholar · View at Scopus
  19. M. Hirano, K. Maeda, S. Matsushima, Y. Nozaki, H. Kusuhara, and Y. Sugiyama, “Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin,” Molecular Pharmacology, vol. 68, no. 3, pp. 800–807, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. W. Jacobsen, G. Kirchner, K. Hallensleben et al., “Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver,” Drug Metabolism and Disposition, vol. 27, no. 2, pp. 173–179, 1999. View at Google Scholar
  21. Y. Gotoh, H. Suzuki, S. Kinoshita, T. Hirohashi, Y. Kato, and Y. Sugiyama, “Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 292, no. 1, pp. 433–439, 2000. View at Google Scholar · View at Scopus
  22. R. Masereeuw, S. Notenboom, P. H. E. Smeets, A. C. Wouterse, and F. G. M. Russel, “Impaired renal secretion of substrates for the multidrug resistance protein 2 in mutant transport-deficient (TR) rats,” Journal of the American Society of Nephrology, vol. 14, no. 11, pp. 2741–2749, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Ito, H. Suzuki, T. Hirohashi, K. Kume, T. Shimizu, and Y. Sugiyama, “Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR,” American Journal of Physiology, vol. 272, no. 1, pp. G16–G22, 1997. View at Google Scholar · View at Scopus
  24. P. Borst, R. Evers, M. Kool, and J. Wijnholds, “A family of drug transporters: the multidrug resistance-associated proteins,” Journal of the National Cancer Institute, vol. 92, no. 16, pp. 1295–1302, 2000. View at Google Scholar · View at Scopus
  25. T. Komai, K. Kawai, T. Tokui et al., “Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 17, no. 2, pp. 103–113, 1992. View at Google Scholar · View at Scopus
  26. T. Abe, M. Kakyo, H. Sakagami et al., “Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2,” The Journal of Biological Chemistry, vol. 273, no. 35, pp. 22395–22401, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Hagenbuch and P. J. Meier, “The superfamily of organic anion transporting polypeptides,” Biochimica et Biophysica Acta, vol. 1609, no. 1, pp. 1–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Hsiang, Y. Zhu, Z. Wang et al., “A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters,” The Journal of Biological Chemistry, vol. 274, no. 52, pp. 37161–37168, 1999. View at Publisher · View at Google Scholar · View at Scopus